Aim: TMC114 is a new HIV protease inhibitor, used in combination with low-dose ritonavir (TMC114/r) as a pharmacokinetic enhancer. Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor. Both antiretrovirals show activity against wild-type and resistant HIV. An open-label crossover study was conducted in HIV - healthy volunteers to investigate the potential for a pharmacokinetic interaction between TMC114/r and tenofovir. Methods: Two groups, each of six volunteers, were evaluated in two consecutive sessions. In session 1, volunteers received TMC114/r (300/100 mg bid) for 7 days, followed by a wash-out period of at least 6 days. In session 2, volunteers received TMC114/r (300/100 mg bid) plus TDF (300 mg qd). Results: When TMC114/r and TDF were coadministered, tenofovir plasma concentrations (Cmin and Cmax), and area under the curve (AUC24 h) increased by 37%, 24% and 22%, respectively. When TDF and ritonavir were coadministered, TMC114 plasma Cmin, Cmax and AUC12 h increased by 24%, 16% and 21%, respectively. There were no changes in the urinary excretion of unchanged tenofovir or TMC114 during coadministration. Administration of TMC114/r in HIV- healthy volunteers with or without TDF was well tolerated. Conclusions: The interaction between TMC114/r and tenofovir is not clinically relevant and no dose adjustments are required when these drugs are coadministered. © 2007 The Authors.
CITATION STYLE
Hoetelmans, R. M. W., Mariën, K., De Pauw, M., Hill, A., Peeters, M., Sekar, V., … Lefebvre, E. (2007). Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. British Journal of Clinical Pharmacology, 64(5), 655–661. https://doi.org/10.1111/j.1365-2125.2007.02957.x
Mendeley helps you to discover research relevant for your work.